C3L-02660
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 72.14510609
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.550
- TNFA_SIGNALING_VIA_NFKB+0.540
- ANGIOGENESIS+0.450
- HEDGEHOG_SIGNALING+0.400
- MYOGENESIS+0.370
- COAGULATION+0.320
- TGF_BETA_SIGNALING+0.320
- IL2_STAT5_SIGNALING+0.300
- MYC_TARGETS_V2+0.290
- INFLAMMATORY_RESPONSE+0.280
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.520
- PROTEIN_SECRETION-0.340
- OXIDATIVE_PHOSPHORYLATION-0.320
- PANCREAS_BETA_CELLS-0.300
- PEROXISOME-0.220
- FATTY_ACID_METABOLISM-0.210
- GLYCOLYSIS-0.200
- INTERFERON_GAMMA_RESPONSE-0.180
- SPERMATOGENESIS-0.170
- PI3K_AKT_MTOR_SIGNALING-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-D6-8568-01A-11R-2403-07 | — | — | 0.797 |
| 2 | C3N-02289 | — | cohortSQ1 | 0.795 |
| 3 | TCGA-LL-A5YP-01A-21R-A28M-07 | — | E | 0.793 |
| 4 | TCGA-BL-A5ZZ-01A-31R-A30C-07 | — | — | 0.779 |
| 5 | SRR8613814 | — | D | 0.776 |
| 6 | TCGA-85-8353-01A-21R-2296-07 | — | cohortSQ1 | 0.774 |
| 7 | SRR12475169 | — | — | 0.760 |
| 8 | b9cadac9-9bb4-4bc8-9303-d05ad06778cc | — | — | 0.759 |
| 9 | TCGA-A7-A6VV-01A-22R-A33J-07 | — | E | 0.759 |
| 10 | BS_QP6MSKRE | Spinal Cord Ependymoma | — | 0.757 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.550 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.540 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.450 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.400 | Inavolisib | — uncovered |
| MYOGENESIS | 0.370 | Inavolisib | — uncovered |
| COAGULATION | 0.320 | Binimetinib | — uncovered |
| TGF_BETA_SIGNALING | 0.320 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.300 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.290 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.280 | Idelalisib | — uncovered |
| HYPOXIA | 0.250 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.230 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.230 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.230 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.210 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.180 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.150 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.150 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.130 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.130 | Idelalisib | — uncovered |